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The immunoglobulin VH gene mutation status can divide B-cell chronic lymphocytic leukaemia (CLL) into two entities with a different
clinical course. Cases with unmutated VH genes, considered to evolve from pregerminal centre (GC) cells, have a worse outcome
compared to cases showing mutated VH genes, that is, post-GC derived. Also, telomere length has been reported to be of prognostic
significance in CLL. Interestingly, telomerase becomes activated during the GC reaction and an elongation of the telomeres occurs in
GC B cells. We performed telomere length and VH gene analysis in a series of 61 CLL cases, in order to investigate if the unique
telomere lengthening shown in GC B cells could reflect the telomere status in the two subsets of mutated and unmutated CLL. A
novel association was found between VH gene mutation status and telomere length, since significantly shorter telomeres were
demonstrated in the unmutated group compared to the mutated group (mean length 4.3 vs 6.3kbp). Shorter telomeres also
constituted a subgroup with a worse prognosis than cases with longer telomeres (median survival 59 vs 159 months). Furthermore,
the Ig gene sequence data revealed that samples with high mutations frequency (46%) had long telomeres (B8kbp). Thus, both the
telomere and VH gene mutation status in CLL appear linked, which may reflect the proliferative history of the clonal cells with regard
to the GC reaction.
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B-cell chronic lymphocytic leukaemia (CLL) is characterised by a
monoclonal expansion of small B lymphocytes, typically expres-
sing CD5, CD19, CD23 and low levels of surface immunoglobulin
(Ig) (Matutes et al, 1994), which previously were supposed to
originate from naive B cells of the mantle zone. However, recent
analyses of the Ig heavy-chain variable region (IgVH) gene have
defined two subsets of CLL, comprising cases with somatically
unmutated or mutated VH genes (Fais et al, 1998; Hamblin et al,
1999; Damle et al, 1999). The unmutated cases are considered to
originate from pregerminal centre (GC) B cells and the mutated
from post-GC B cells. A more favourable prognosis has been
shown for CLL cases with somatically mutated VH genes compared
with unmutated cases (Hamblin et al, 1999; Damle et al, 1999;
Maloum et al, 2000; Thunberg et al, 2001), indicating that CLL can
be separated into at least two entities with a different clinical
outcome.
Human telomeres in normal somatic cells consist of 6–12kbp of
TTAGGG-repeats that are eroded upon cell division because of the
so-called ‘end-replication problem’ (Moyzis et al, 1988; Blackburn,
1991; Levy et al, 1992). A decrease in telomere length has been
demonstrated with cell division in vitro and with cellular age in
vivo for different cell types and tissues. At a critical telomere length
during shortening, an ageing programme is activated in normal
cells (Allsopp et al, 1992, 1995a,b). Thus, the telomere length can
predict and limit the number of divisions a cell can undergo. This
telomere erosion, however, can be counteracted by the telomerase
complex, which has a reverse transcriptase activity and can
synthesise new telomeric repeats (Morin, 1989). Telomerase
activity is linked to cells with an extended or infinite division
potential, such as stem cells, germline cells and lymphocytes as
well as permanent cell lines and tumor cells, while telomerase
activity is absent from most normal somatic cells (Kim et al, 1994;
Hiyama et al, 1995; Ha ¨rle-Bachor and Boukamp, 1996; Norrback
et al, 1996; Norrback and Roos, 1997). Recently, high levels of
telomerase activity have been demonstrated in normal GC B cells
in association with a unique telomere lengthening process not
demonstrated in other cell types in vivo (Hu et al, 1997; Weng et al,
1997; Norrback et al, 2001).
Different levels of telomerase activity are expressed in the vast
majority of leukaemias and malignant lymphomas (Norrback and
Roos, 1997). In acute myeloid leukaemia, relapse cases demon-
strate higher telomerase activity levels compared to that at
diagnosis and similar findings have been reported for advanced
CLL cases (Counter et al, 1995; Ohyashiki et al, 1997; Xu et al,
1998). These data indicate that the expression of telomerase
activity can be associated with tumour progression in haemato-
logical neoplasms. Regarding CLL, one study has shown that both
the telomere length and telomerase activity level were significant
prognostic markers, since a short median survival was significantly
associated with short telomere length (o6kbp) and high telo-
merase activity (Bechter et al, 1998). If the telomere lengthening in Revised 14 November 2002; accepted 21 November 2002
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relevance in this context, CLL cases of post-GC type should then be
expected to have longer telomeres than pre-GC CLL.
In the present study, we have analysed a series of CLL cases for
VH mutation status by sequencing of the clonal rearrangements,
for telomere length by Southern blotting and for clinical outcome.
We have found an association between VH mutation status and
telomere length with shorter telomeres in unmutated (pre-GC) CLL
cases compared with mutated (post-GC) CLL. Furthermore, a
relationship between VH mutation and telomere length was
demonstrated since a gradual increase in telomere length was
shown to parallel a decrease in homology to VH germline
sequences, that is, an increase in mutation rate.
MATERIALS AND METHODS
Patients
Frozen tumour samples from 61 patients were studied, which were
identified in the archives of the departments of Pathology at
Uppsala University Hospital and Umea ˚ University Hospital
between 1981 and 1998. The tumour material was obtained from
bone marrow (29 cases), peripheral blood (26 cases), spleen (five
cases) and lymph node (one case). There were 43 men and 18
women. Survival data were available for 56 patients from the local
Swedish population and cancer registries in Uppsala and Umea ˚.
The median age at diagnosis was 65 years and the median survival
time was 82 months. Patient follow-up ranged from 8 to 182
months with a median follow-up of 56 months. The present study
was approved by the ethical committee.
Morphology and immunophenotyping
Classification was performed on smears, sections, imprints and by
immunophenotyping using flow cytometry. According to the Royal
Marsden scoring system the tumour cells expressed CD5, CD19
and CD23, and a weak expression of Ig (Matutes et al, 1994).
PCR amplification and nucleotide sequencing analysis
High molecular weight DNA was prepared from frozen tumour
material using standard protocols including proteinase K treat-
ment, chloroform treatment and ethanol precipitation. VH gene
family-specific PCR amplification was performed using six family-
specific VH primers and one JH primer as previously described (Li
et al, 1999). Monoclonal PCR products were distinguished from
polyclonal by a single-strand conformation polymorphism analysis
using polyacrylamide gel or GenePhor electrophoresis according to
the manufacturer’s protocol (Amersham Pharmacia biotech,
Uppsala, Sweden).
The clonal PCR products were sequenced directly using the
BigDye Terminator Cycle Sequencing Reaction Kit (Perkin-Elmer,
ABI, FosterCity, CA, USA) or using cloning as previously described
(Li et al, 1999). All sequence reactions were analysed using an
automated DNA sequencer (ABI 377, Applied Biosystems, Foster
City, CA, USA).
Analysis of VH, D and JH sequences
The sequences were aligned to IgH sequences from the BLAST
database (National Center for Biotechnology Information, USA),
the V-BASE database (MRC, Centre for Protein Engineering,
Cambridge, UK) and the Immunogenetics database (http://
imgt.cines.fr:8104, initiator and coordinator: Marie-Paule Lefranc,
Montpellier, France). A VH gene sequence deviating more than 2%
from the corresponding germline gene was defined as mutated
(Matsuda et al, 1993).
Southern blotting
Southern blotting and hybridisation with the telomeric probe
(TTAGGG)4 were performed and mean telomere restriction
fragment (TRF) length was calculated as previously described
(Mehle et al, 1994). As molecular weight standards, the lambda
DNA/Eco1 Styl/Mlu1 Marker (MBI Fermentas Inc., Amherst, NY,
USA) and the DNA molecular weight marker X (Boehringer
Mannheim Gmbh, Germany) were used. The peak TRF value was
estimated as the length corresponding to the point with the highest
optical density within the TRF profile.
hTERT mRNA expression
In 19 cases with material available for RNA extraction, hTERT
mRNA levels were analysed as previously described (Norrback
et al, 2001) using a real-time polymerase chain reaction. The
amount of hTERT mRNA was quantified using the Light Cycler
Telo TAGGG hTERT Quantification kit where hTERT RNA levels
were expressed as a ratio between the expression level of hTERT
RNA and a house-keeping gene RNA (porphobilinogen deami-
nase) according to the manufacturer’s protocol (Roche, Basel,
Switzerland).
Statistical analyses
Kaplan–Meier survival curves and the log-rank test were
performed to study the prognostic significance of VH gene
mutations and telomere length in CLL using the Statistica 5.5
software (Stat Soft Inc., Tulsa, USA). Survival was calculated from
the date of diagnosis until the last follow-up or death. Independent
samples t-test was used to compare means, and nonparametric
correlation was calculated according to the Spearman rank
correlation. Probabilities of less than 0.05 were accepted as a
significant value.
RESULTS
Analysis of VH gene mutations
A total of 34 cases (56%) demonstrated unmutated VH genes and
27 cases (44%) somatically mutated VH genes. In the mutated
cases, the mutation frequency ranged from 2.1–11.7%. Two clonal
rearrangements were found in six cases, five of which showed two
unmutated VH genes, whereas one case had one unmutated and
one mutated (97.7% homology) VH gene. The last case was
considered as mutated and the first five cases as unmutated.
Telomere length and Ig gene mutation status
A summary of the data is given in Table 1. The mean peak TRF
length was 5.16kbp and the median peak TRF length was 4.57kbp,
range 2.35–10.10kbp. The reason for using peak TRF values in the
further analysis was that 10 cases had two peaks and for these the
value of the largest peak was used, since all cases had 450%
Table 1 Telomere length in relation to immunoglobulin VH gene
mutation status in a series of 61 CLL cases
Mean TRF (kbp) Peak TRF (kbp)
VH gene status Mean Median Range Mean Median Range
Unmutated (n=34) 4.29 4.24 3.06–5.62 4.29 4.24 2.35–7.66
Mutated (n=27) 5.36 5.07 3.30–7.36 6.25 5.69 2.66–10.10
All cases (n=61) 4.76 4.49 3.06–7.36 5.16 4.57 2.35–10.10
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cases with double peaks had only one clonal Ig gene rearrange-
ment.
A total of 34 unmutated and 27 mutated samples were analysed
for telomere length. The unmutated cases demonstrated a median
peak TRF length of 4.24kbp (mean peak 4.29kbp, range 2.35–
7.66kbp) compared with 5.69kbp (mean peak 6.25kbp, range
2.66–10.10kbp) for the mutated cases. The association between
mutation status and telomere length (Figure 1) was significant
using the Spearman rank correlation (R
2¼0.46, Po0.001).
Thus, the IgVH gene mutation status correlated with TRF length.
For cases with no somatic hypermutations (i.e. 100% homology to
the germline gene), the TRF length was B4kpb and for cases with
a high mutation rate (o94% homology to the germline gene), the
TRF length was B8kbp. The material was divided into two groups
of equal size with a cutoff at the median peak TRF value (4.57kbp).
The presence of hTERT RNA was detected in all the 19 cases
studied. Using independent samples’ t-test, a significant associa-
tion (P¼0.032) was found between long telomeres (TRF
44.57kbp) and low hTERT mRNA levels and vice versa (data
not shown). No association was found between mutation status
and hTERT mRNA levels.
Survival analysis
Survival curves were plotted according to the Kaplan–Meier
method using data available on 56 patients. The survival data were
grouped into mutated (26 patients) and unmutated (30 patients)
cases and a statistically significant difference in overall survival
was found between these two groups (Po0.001) (Figure 2). The
median survival for patients with mutated VH genes was 138
months and for those without mutations 55 months, calculated
from the date of diagnosis. The median age was 63 years for
patients with unmutated VH genes and 67 years for patients with
mutated VH genes.
Regarding telomere length, survival analysis was performed
after dividing the material into two groups with a cutoff at the
median peak TRF value (4.57kbp). A significant difference in
survival was found between the two groups with a better overall
survival for cases with peak TRF values 44.57kbp (P¼0.0015)
(Figure 3). The median survival for patients with telomeres longer
than the cutoff value was 159 months and for those with shorter
telomeres 59 months. The median age was 62 years for patients
with TRF lengths o4.57kbp and 67 years for cases with TRF
lengths 44.57kbp. Using Cox regression analysis neither mutation
status nor telomere length were independent variables, indicating
an association between these two parameters.
DISCUSSION
Convincing data have made it probable that CLL consists of at least
two variants derived from different subpopulations of neoplastic
cells (Fais et al, 1998; Damle et al, 1999; Hamblin et al, 1999;
Maloum et al, 2000), one originating from unmutated pre-GC cells
and the other from somatically hypermutated GC or post-GC cells.
This notion was further supported by the observation that patients
with mutated VH genes had a significantly better outcome
compared to patients lacking VH gene mutations (Damle et al,
1999; Hamblin et al, 1999; Maloum et al, 2000; Thunberg et al,
2001). In the present study, we were able to verify these data
regarding prognosis and VH gene mutation status, since our
mutated CLL cases displayed more than twice as long median
survival than the unmutated cases (138 vs 55 months). Most
interestingly, we found a novel association between VH gene
mutation frequency and telomere length, showing significantly
longer telomeres in CLL cases having somatically mutated VH
genes. We could also demonstrate that CLL cases with longer
telomeres had a significantly better prognosis than cases with
shorter telomeres (159 vs 59 months), supporting a previously
published study (Bechter et al, 1998). But what could be the
biological explanation for this new association coupling together
our findings?
Normal lymphocytes have been shown to lose telomeres with
each cell division in vivo and in vitro (Vaziri et al, 1994; Weng et al,
1995; Norrback and Roos, 1997; Rufer et al, 1998). However, GC B
cells are characterised by telomerase activity and a unique
telomere lengthening process has been demonstrated in crude
preparations of GC B cells (Hu et al, 1997; Weng et al, 1997;
Norrback et al, 2001). In immunopurified cell populations from
tonsils, we found a telomere lengthening in both the centroblast
and centrocyte populations (Norrback et al, 2001). The telomere
length increase is likely to occur in proliferating pre-GC blasts and
centroblasts, since telomerase activity is coupled to cell cycle
progression in lymphocytes (Buchkovich and Greider, 1996;
Igarashi and Sakaguchi, 1997). In cells maturing from naive B
cells to centroblasts/centrocytes, we could therefore demonstrate a
telomere lengthening of up to 4kbp in individual cases (Norrback
et al, 2001).
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Figure 1 Correlation between telomere length in kbp and VH gene mutation frequency given as percent homology with germline (r
2¼0.46, Po0.001).
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telomeres than the unmutated. We therefore believe that this
difference in telomere length between mutated and unmutated CLL
reflects, and supports the theory, that these subsets probably
originate from different stages in the B-cell development, that is,
pre- and post-GC B cells. Interestingly, the difference in telomere
length between pre-GC and post-GC cells seemed to be preserved
in the CLL cases, which may indicate a similar rate of telomere loss
in the different CLL clones. The shorter telomere lengths in
unmutated and mutated CLL compared to normal pre-GC and GC
B cells (Norrback et al, 2001) could, at least partly, be explained by
telomere loss normally occurring during ageing, since most of the
normal GC B cells studied by us were derived from tonsils from
young individuals whereas the CLL cases represented an older
patient group.
Telomerase is activated in the vast majority of leukaemias and
malignant lymphomas, including CLL (reviewed in Norrback and
Roos, 1997). In a subset of our CLL cohort (n¼19), we have
analysed the mRNA levels of the catalytic unit of telomerase,
hTERT, which have been shown to correlate with the telomerase
activity in B lymphocytes (Liu et al, 1999; Norrback et al, 2001).
We found that CLL cases with longer telomeres had lower hTERT
mRNA levels than cases with shorter telomeres, which is in line
with a previously published report on telomerase activity (Bechter
et al, 1998). These collected data argue that the difference in
telomere lengths between the two groups seemed unrelated to
hTERT RNA levels (and thus telomerase activity), and rather
reflected the telomere status of the primarily transformed cells.
One common denominator for telomerase activation and the VH
gene hypermutation mechanism in the GC is an active cell cycle.
Somatic VH gene hypermutations occur in growing B cells given
the survival signals based on antigen selection, and in these cells
telomerase is known to be upregulated as discussed above. The
combined telomere length and VH gene hypermutation analysis
presented here might give new insights into the kinetics of the
hypermutation machinery. It can be anticipated that the total
telomere length increase is a result of the number of cell cycle
rounds undergone in the GC. Thus, the data suggest that a limited
number of VH gene mutations occur for each GC cell division
round since post-GC B cells with long telomeres had high VH gene
mutation frequencies. This association between VH gene mutation
status and telomere length provides new possibilities for more
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Figure 2 Survival data for VH gene mutated (26 patients) and unmutated (30 patients) cases demonstrating a significant difference in overall survival
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that an alternative way to acquire somatic VH gene mutations has
been described in the hyper-IgM syndrome because of a
nonfunctional CD40–CD154 interaction leading to no develop-
ment of germinal centres (Durandy and Honjo, 2001). However,
the mutation frequency in the hyper-IgM syndrome (usually
o2%) (Chu et al, 1995; Monson et al, 2001; Weller et al, 2001) is
below the cutoff level used to distinguish between mutated and
unmutated CLL cases. Hence, it seems unlikely that the mutated
CLL cases had acquired VH gene mutations by the alternative
CD40-independent pathway.
Finally, the survival data also suggest that telomere length can be
an important clinical parameter to study for the evaluation of CLL
in the diagnostic setting, since longer telomere lengths were
associated with better clinical outcome. We have chosen the
median value as cutoff level, but the true border to divide the
material into prognostic groups deserves further investigation.
Recently described techniques for flow cytometric analysis after in
situ hybridisation with a fluorochrome labelled telomere
probe (‘flow-FISH’) can be useful (Rufer et al, 1998; Hultdin et al,
1998), since the flow-FISH approach is convenient and can be
directly applied to material sent for regular diagnostic work.
However, further studies of larger groups of patients have to be
performed to clarify the clinical impact of telomere length analysis
in CLL.
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